Sensitivity to voltage-independent inhibition determined by pore-lining region of the acetylcholine receptor.
Some noncompetitive inhibitors (e.g., ganglionic blockers) exhibit selectivity for the inhibition of neuronal nicotinic acetylcholine receptors (nAChRs). This study characterizes the mechanism of selective long-term inhibition of neuronal and muscle-neuronal chimeric nAChRs by bis(2,2,6,6-tetramethyl-4-piperidinyl) sebacate (bis-TMP-10 or BTMPS), a bifunctional form of the potent ganglionic blocker tetramethylpiperidine. Long-term inhibition of neuronal nAChRs by bis-TMP-10 has been previously demonstrated to arise, at least in part, from the binding of the bis compound to neuronal beta-subunits. In this study, long-term inhibition is demonstrated to be dependent upon the presence of sequence element(s) within the pore-lining second transmembrane domain (tm2) of neuronal beta-subunits; however, the inhibitor binding site itself does not appear to be contained within the segment of the channel pore influenced by the membrane electric field. Specifically, our results imply that bis-TMP-10 interacts with an activation-sensitive element, the availability of which may be regulated by a sequence in the tm2 domain. Furthermore, we demonstrate a compound length requirement for long-term inhibition that would be consistent with binding to multiple sites located on the extracellular portion of the receptor.
Francis
M M
MM
Department of Neuroscience, University of Florida, Gainesville 32610, USA.
Choi
K I
KI
Horenstein
B A
BA
Papke
R L
RL
D000109:Acetylcholine / Q000494:pharmacology; D000595:Amino Acid Sequence; D000818:Animals; D003652:Decanoic Acids / Q000138:chemical synthesis / Q000494:pharmacology*; D005260:Female; D046911:Macromolecular Substances; D008969:Molecular Sequence Data; D018482:Muscle, Skeletal / Q000502:physiology; D009474:Neurons / Q000502:physiology; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D009865:Oocytes / Q000502:physiology; D018408:Patch-Clamp Techniques; D010880:Piperidines / Q000138:chemical synthesis / Q000494:pharmacology*; D018075:RNA, Complementary; D051381:Rats; D011978:Receptors, Nicotinic / Q000096:biosynthesis / Q000737:chemistry / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D014158:Transcription, Genetic; D014982:Xenopus laevis
D003652:Decanoic Acids; D046911:Macromolecular Substances; D018733:Nicotinic Antagonists; D010880:Piperidines; D018075:RNA, Complementary; D011978:Receptors, Nicotinic; D011993:Recombinant Fusion Proteins; C083752:Tinuvin 770; D000109:Acetylcholine